-
5-Azacytidine Reprograms Dormant Disseminated Cancer Cells
2026-08-12
Singh et al. show that 5-Azacytidine combined with retinoic acid agonists can reprogram disseminated cancer cells into a stable, nonproliferative state that limits metastatic outgrowth. The study links this effect to restoration of TGF-β-SMAD4 signaling and provides a mechanistic framework for studying therapeutic control of cancer dormancy.
-
3-Deazaneplanocin (DZNep): Applied Research Guide
2026-08-12
Learn how to deploy DZNep in AML apoptosis, hepatocellular carcinoma research, sphere assays, and epigenetic profiling. This workflow emphasizes receptor-aware experimental design, dose and time optimization, orthogonal readouts, and troubleshooting for reproducible results.
-
Carbapenemase Gene Spread in Enterobacter cloacae
2026-08-11
A 2025 BMC Microbiology study mapped carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals. Its combination of gene localization, conjugation testing, mobile-element analysis, and strain typing shows that blaNDM-1 was frequently plasmid-associated and readily transferable, providing a useful framework for resistance surveillance and bacterial infection model design.
-
Pyridostatin: From G4 Structure to Assay Logic
2026-08-11
Pyridostatin research is strongest when structural stabilization is connected to orthogonal cellular readouts. This guide distinguishes DNA and RNA G-quadruplex biology, interprets telomere phenotypes, and translates recent TDP-43 findings into more rigorous assay decisions.
-
Thiazovivin A5506: Practical ROCK Inhibitor Guide
2026-08-10
Thiazovivin (A5506) is a ROCK inhibitor used to support fibroblast reprogramming and human embryonic stem cell survival after dissociation. This guide covers product handling, workflow setup, and QC while defining research-only boundaries where working concentrations, exposure times, and direct matched paper evidence are unavailable.
-
5-Azacytidine Triggers DNA Damage in Myeloma Cells
2026-08-09
The reference study shows that 5-Azacytidine kills therapy-sensitive and therapy-resistant multiple myeloma cells through ATR-associated DNA double-strand break responses and coordinated apoptotic pathways. Its synergy with doxorubicin and bortezomib provides a mechanistic rationale for combination studies, while the cellular model design highlights important variables for translational interpretation.
-
GPNMB Model Predicts ESCC Immunotherapy Response
2026-08-08
This study identifies circulating soluble GPNMB as a mechanistic biomarker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By combining plasma GPNMB, CAF–epithelial niche features, and clinicopathologic variables, the authors establish a multimodal framework that links tumor–immune biology with clinically actionable response prediction.
-
Aurora A Overexpression in High-Risk Retinoblastoma
2026-08-07
A 2024 study identifies Aurora kinase A (AURKA) overexpression as a frequent feature of human retinoblastoma and links it to histopathologic high-risk factors and poor chemotherapy response. By combining patient-tissue analysis with genetic and pharmacologic perturbation, the work supports AURKA as a mechanistically relevant target while highlighting the need for disease-specific validation.
-
FLOT1-FOSL2-EphA2 Axis Modulates Microglial Polarization in
2026-08-07
This study elucidates how the FLOT1-FOSL2 interaction promotes EphA2 transcription, activating microglial pro-inflammatory polarization via the p38/MAPK pathway in Alzheimer’s disease (AD) models. The findings reveal a mechanistic target for modulating neuroinflammation and cognitive outcomes in AD, with direct implications for neurodegenerative disease research workflows.
-
SGC-CBP30: Selective CREBBP/EP300 Bromodomain Inhibition
2026-08-06
SGC-CBP30 is a potent CREBBP/EP300 bromodomain inhibitor with nanomolar selectivity, enabling precise study of transcriptional coactivator inhibition in epigenetics and cancer biology research. Its validated activity in cellular assays and robust solubility profile make it a benchmark reagent for dissecting super-enhancer function and TGF-β/SMAD3 signaling. The compound is supplied by APExBIO for advanced laboratory applications.
-
Sumatriptan’s Emerging Anti-Inflammatory Role: Systematic Re
2026-08-06
This article analyzes a systematic review revealing sumatriptan’s anti-inflammatory actions beyond its established anti-migraine use. Key innovation lies in demonstrating that sumatriptan modulates inflammatory pathways and markers at low doses, suggesting potential for repositioning as an anti-inflammatory agent in diverse disease models.
-
Selective Inhibition of Aminopeptidases by ACE Inhibitors
2026-08-05
This study by Tieku and Hooper systematically re-evaluates the specificity of ACE inhibitors and related metallopeptidase inhibitors against mammalian aminopeptidases N, A, and W. The work clarifies the selectivity profiles of these compounds, resolving longstanding ambiguities in enzyme inhibition assays and guiding more precise experimental design in hypertension, heart failure, and renal research.
-
Carbapenemase Genes in CREC: Prevalence and Transmission Ins
2026-08-05
A multicenter study in Guangdong, China, has revealed high prevalence and efficient transfer of carbapenemase-encoding genes (CEGs)—notably blaNDM-1—in carbapenem-resistant Enterobacter cloacae (CREC). The research details genomic contexts, resistance patterns, and transmission dynamics during the COVID-19 pandemic, offering actionable insights for molecular epidemiology and antibiotic stewardship.
-
Dual DNMT and Tubulin Inhibition by H62 Blocks Leukemia Prog
2026-08-04
This study introduces H62, a novel letermovir derivative that simultaneously targets DNA methyltransferase (DNMT) and β-tubulin, yielding potent anti-leukemic effects in cell and mouse models. The dual-action mechanism disrupts microtubule dynamics and epigenetic regulation, offering a promising strategy for treating aggressive leukemias resistant to standard therapies.
-
LGK-974: Translating PORCN Inhibition Into Precision Wnt Can
2026-08-04
Explore how LGK-974, a leading PORCN inhibitor, enables precise modeling of Wnt-driven cancers—especially pancreatic tumors with RNF43 mutations—through advanced mechanistic insights and practical assay guidance. This article uniquely bridges recent literature and real-world protocol optimization.